STOCK TITAN

Charles River (CRL) EVP Victoria Creamer exercises options and sells 4,179 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. reported that EVP & Chief People Officer Victoria L. Creamer exercised stock options for 4,179 shares of common stock on 2026-08-06 at an exercise price of $179.66 per share and immediately sold 4,179 shares of common stock at $259.16 per share. The exercised options covered 4,179 shares and now show 0 derivative shares remaining from this grant.

Positive

  • None.

Negative

  • None.
Insider Creamer Victoria L
Role EVP & Chief People Officer
Sold 4,179 shs ($1.08M)
Approx. gross sale proceeds $1.08M
Approx. exercise cost $751K
Approx. pre-tax spread $332K
Type Security Shares Price Value
Exercise Stock Options (Right to Buy) 4,179 $0.00 $0.00
Exercise Common Stock 4,179 $179.66 $751K
Sale Common Stock 4,179 $259.16 $1.08M
Holdings After Transaction: Stock Options (Right to Buy) — 0 shares (Direct); Common Stock — 30,051 shares (Direct)
Options exercised 4,179 shares Stock options (right to buy) exercised on 2026-08-06
Option exercise price $179.66 per share Conversion or exercise price for 4,179 options
Shares sold 4,179 shares Common stock sale on 2026-08-06 following option exercise
Sale price $259.16 per share Per-share price for 4,179 common shares sold
Options expiration 2030-05-29 Expiration date of the exercised stock options
Derivative shares remaining from grant 0 shares Total shares following transaction for this option position
Stock Options (Right to Buy) financial
"security_title: Stock Options (Right to Buy)"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
derivative financial
"transaction_type: derivative"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did CRL executive Victoria L. Creamer report?

Victoria L. Creamer reported exercising stock options for 4,179 shares of Charles River Laboratories common stock and selling 4,179 shares on 2026-08-06 in a same-day exercise-and-sell transaction.

At what price were Victoria L. Creamer’s CRL stock options exercised and shares sold?

The options were exercised at an exercise price of $179.66 per share, and the resulting 4,179 shares of Charles River Laboratories common stock were sold at $259.16 per share on 2026-08-06.

How many CRL options did Victoria L. Creamer exercise in this Form 4 filing?

Victoria L. Creamer exercised stock options covering 4,179 shares of Charles River Laboratories common stock, originally exercisable at $179.66 per share, and then sold the same number of shares on the transaction date.

What is the expiration and grant exercise date of the CRL options exercised by Victoria L. Creamer?

The exercised Charles River Laboratories options had an exercise date of 2021-05-29 and an expiration date of 2030-05-29, and were fully exercised for 4,179 underlying shares in this transaction.

Does the Form 4 indicate remaining derivative positions for Victoria L. Creamer in this CRL option grant?

For this specific option grant, the Form 4 shows 0 derivative shares remaining after exercising 4,179 options. The derivative position tied to this grant was fully used in the reported exercise.

Was Victoria L. Creamer’s CRL stock sale reported as a planned 10b5-1 transaction?

The filing’s Rule 10b5-1 plan checkbox is not marked as affirming a trading plan, and no footnote indicates a 10b5-1 arrangement for these Charles River Laboratories transactions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Creamer Victoria L

(Last)(First)(Middle)
C/O CHARLES RIVER LABORATORIES
251 BALLARDVALE STREET

(Street)
WILMINGTON MASSACHUSETTS 01887

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & Chief People Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/06/2026M4,179A$179.6634,230D
Common Stock08/06/2026S4,179D$259.1630,051D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$179.6608/06/2026M4,17905/29/202105/29/2030Common Stock4,179$00D
Explanation of Responses:
/s/ Victoria L. Creamer08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)